Literature DB >> 1666354

Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration.

Y Ohtake1, H Hirasawa, T Sugai, S Oda, H Shiga, K Matsuda, N Kitamura.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1666354     DOI： 10.1159/000420222

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN： 0302-5144            Impact factor:   1.580


× No keyword cloud information.
  14 in total

Review 1.  Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?

Authors:  H M Oudemans-van Straaten; J P J Wester; A C J M de Pont; M R C Schetz
Journal:  Intensive Care Med       Date:  2006-02-02       Impact factor: 17.440

2.  Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation.

Authors:  Sang Jin Han; Hyoung Soo Kim; Kun Il Kim; Sung Mi Whang; Kyung Soon Hong; Won Ki Lee; Sun Hee Lee
Journal:  J Korean Med Sci       Date:  2011-06-20       Impact factor: 2.153

3.  Inhibition of nuclear factor-κB enhances the antitumor effect of paclitaxel against gastric cancer with peritoneal dissemination in mice.

Authors:  Koichiro Haruki; Hiroaki Shiba; Yuki Fujiwara; Kenei Furukawa; Ryota Iwase; Tadashi Uwagawa; Takeyuki Misawa; Toya Ohashi; Katsuhiko Yanaga
Journal:  Dig Dis Sci       Date:  2012-07-18       Impact factor: 3.199

4.  Effect of nafamostat mesilate on Na+ and K+ transport properties in the rabbit cortical collecting duct.

Authors:  S Muto; M Imai; Y Asano
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

5.  Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study.

Authors:  Mehran Monchi; Denis Berghmans; Didier Ledoux; Jean-Luc Canivet; Bernard Dubois; Pierre Damas
Journal:  Intensive Care Med       Date:  2003-11-05       Impact factor: 17.440

6.  Mechanisms of the hyperkalaemia caused by nafamostat mesilate: effects of its two metabolites on Na+ and K+ transport properties in the rabbit cortical collecting duct.

Authors:  S Muto; M Imai; Y Asano
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

Review 7.  A review of continuous renal replacement therapy.

Authors:  C G Flynn
Journal:  Ir J Med Sci       Date:  1994-07       Impact factor: 1.568

8.  Single-center experience of extracorporeal membrane oxygenation mainly anticoagulated with nafamostat mesilate.

Authors:  Woosik Han; Jin San Bok; Hyun Jin Cho; Jae Hyeon Yu; Myung Hoon Na; Shinkwang Kang; Min-Woong Kang
Journal:  J Thorac Dis       Date:  2019-07       Impact factor: 2.895

9.  Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study.

Authors:  Yong Kyu Lee; Hae Won Lee; Kyu Hun Choi; Beom Seok Kim
Journal:  PLoS One       Date:  2014-10-10       Impact factor: 3.240

10.  Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial.

Authors:  Ji-Young Choi; Yun-Jeong Kang; Hye Min Jang; Hee-Yeon Jung; Jang-Hee Cho; Sun-Hee Park; Yong-Lim Kim; Chan-Duck Kim
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.